Abstract
In order to develop novel supercritical carbon dioxide (scCO(2))-based processes in the pharmaceutical industry, it is necessary to determine the solubility of drugs in scCO(2). In the current study, the solubility of Febuxostat (FBX), as a reducer the blood uric acid levels in patients with gout, in sc-CO2 was experimentally determined at various temperatures of 308 to 338 K and pressures of 120 to 270 bar. The minimum of the FBX solubility in scCO2 (0.05 x 10-4 of mole fraction) and its maximum value (7.42 x 10-4 of mole fraction) gained at the maximum temperature (338 K) and different pressures of 100 bar and 270 bar. Furthermore, obtained data were correlated by some theoret-ical empirical models; Chrastil and Bartle models with 3 adjustable parameters, Sung and Shim and Hozhabr models with 5 adjustable parameters, and Adachi and Lu and Keshmiri models with 6 adjustable parameters. The models proposed by Keshmiri (AARD% of 10.630 and Rad, of 0.987), and Adachi and Lu (AARD% of 13.304 and Rad, of 0.985) showed the highest accuracy to correlate the experimental data. Also, the total mixing heat (DHtotal), vaporization entalphy (DHvap), and solvation enthalpy (DHsol) of the FBX-scCO2 system were approximately obtained as 37.26 kJ mol-1, 64.79 kJ mol-1, and-27.53 kJ mol-1.(c) 2022 Elsevier B.V. All rights reserved.